deaths from tirzepatide linked to lower risk for death, adverse CV and kidney outcomes vs. GLP-1s Weight-loss drug tirzepatide may lower

Same trough depth

While concerning for many patients, this is a normal consequence of successful weight loss and indicates future body contouring needs

Side effect pattern: Severe or ongoing nausea, dehydration, or constipation can complicate the stimulation phase

Products and statements are not intended to diagnose, treat, cure, or prevent any disease

What Should Storage Notes Clarify for Lab Teams

They may return to a worse body-composition phenotype: more fat mass regained less muscle recovered poorer insulin sensitivity greater metabolic fragility That could help explain why risk appears to rebound so quickly after discontinuation